65,437 trials
Vaccines
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 19.7; 16.9; 17.7; 12.8 percentage of participants
Presbyopia
Primary: Mean Visual Acuity — -0.026; 0.008 logMAR
Presbyopia
Primary: Visual Acuity — 0.023; 0.005 logMAR
Solid Tumors
Primary: Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants
Mucosal Leishmaniasis · Cutaneous Leishmaniasis
Primary: Number of Participants With Clinical Cure of Lesions — 3 Participants
Myopia
Primary: Percentage of Eyes With > Grade 2 Slit Lamp Findings — 0; 0 eyes
Malignant Pleural Mesothelioma
Primary: Number of Subjects Reporting Adverse Events — 38; 22 Participants
Dry Eye
Primary: Percentage of Eyes With Graded Slit Lamp Findings Greater Than Grade 2. — 1; 0 eyes
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance at Week 12 — 0.37; 0.00; 0.13 Wood Units (mmHg/L/min)
Nonepileptic Seizures
Primary: Number of Weekly Psychogenic Non-epileptic Seizure-events — 6.9; 5.3 events
Nonalcoholic Steatohepatitis (NASH) · Primary Sclerosing Cholangitis (PSC)
Primary: Pharmacokinetic (PK) Parameter: AUClast of Cilofexor — 5381.0; 2972.6; 8223.7; 2756.7 h*ng/mL
Presbyopia
Primary: Visual Acuity — 0.079; 0.090 logMAR
Pulmonary Hypertension
Primary: Percentage of Participants With Adverse Events (AEs) Associated With Long-Term Exposure to Ambrisentan — 90.7 percentage of participants
Neuromyelitis Optica Spectrum Disorder
Primary: Annual Relapse Rate — 1; 1.30; 0.51; 0.21 Number of relapses
Heart Failure With Preserved Ejection Fraction
Primary: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. — 894; 1009; 690; 797 Events — p=0.0587